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Abstract
Background: The global disparity in cancer incidence remains a major public health problem. We focused on prostate
cancer since microscopic disease in men is common, but the incidence of clinical disease varies more than 100 fold
worldwide. Ca2+ signaling is a central regulator of cell proliferation, but has received little attention in cancer prevention. We
and others have reported a strong dose-dependent reduction in the incidence of prostate and lung cancer within
populations exposed to boron (B) in drinking water and food; and in tumor and cell proliferation in animal and cell culture
models.
Methods/Principal Findings:We examined the impact of B on Ca2+ stores using cancer and non-cancer human prostate cell
lines, Ca2+ indicators Rhod-2 AM and Indo-1 AM and confocal microscopy. In DU-145 cells, inhibition of Ca2+ release was
apparent following treatment with Ringers containing RyR agonists cADPR, 4CmC or caffeine and respective levels of BA
(50 mM), (1, 10 mM) or (10, 20, 50,150 mM). Less aggressive LNCaP cancer cells required 20 mM BA and the non-tumor cell line
PWR1E required 150 mM BA to significantly inhibit caffeine stimulated Ca2+ release. BA (10 mM) and the RyR antagonist
dantroline (10 mM) were equivalent in their ability to inhibit ER Ca2+ loss. Flow cytometry and confocal microscopy analysis
showed exposure of DU-145 cells to 50 mM BA for 1 hr decreased stored [Ca2+] by 32%.
Conclusion/Significance: We show B causes a dose dependent decrease of Ca2+ release from ryanodine receptor sensitive
stores. This occurred at BA concentrations present in blood of geographically disparate populations. Our results suggest
higher BA blood levels lower the risk of prostate cancer by reducing intracellular Ca2+ signals and storage.
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Introduction
One of the ways cells respond to environmental stimuli is by
opening channels between sites of stored calcium, such as the
endoplasmic reticulum (ER), Golgi, and mitochondria (mt), which
contain high free Ca2+ concentrations (500 mM), and the cytoplasm,
which contains low free Ca2+ concentrations (100 nM) [1]. A rapid
rise in cytoplasmic Ca2+ can be achieved by capacitative calcium
entry (CCE) involving release of stored Ca2+ by the ryanodine
receptor (RyR) and the IP3 receptor (IP3R) into the cytoplasm
followed by an influx of extracellular Ca2+. CCE activates Ca2+
binding proteins that regulate numerous cell functions including
gene transcription, cell proliferation, vesicle secretion, and apoptosis
[2,3]. Cytoplasmic Ca2+ concentrations are returned to normal as
Ca2+ is removed by transporters such as the Na2+- Ca2+ exchanger
in the plasma membrane, the sarcoplasmic endoplasmic ATPase
(SERCA) in the ER membrane, Ca2+ uniporter in mitochondria,
and by binding to high affinity binding proteins [4,5]. In this report
we present evidence that physiological levels of boric acid (BA)
inhibit stored Ca2+ release from RyR agonist sensitive sites.
Boron (B) is the 9th most abundant element in seawater (425 mM
B) and until recently dismissed as biologically irrelevant [6]. B is
bound to oxygen in nature and in physiological fluids 98.4% is
present in the form of B(OH)3 boric acid and 1.6% as B(OH)4
2
borate. Biology has used this element in the structure of several
molecules including: antibiotics in fungi [7]; quorum sensing auto
inducer 2 in bacteria [8]; and the rhamnogalacturonan-II dimer in
plants [9]. In plants, B is required for cell elongation, flowering
and seed formation and is an integral component of food crops.
Non-charged BA crosses the plasma membrane of root epidermal
cells into the cytosol by passive diffusion and this is facilitated by
NIP5; 1 transporters [10]. BA is partially converted to borate in
the cytosol (pKa 9.6) and transported into the xylem using the
export transporter BOR1 [11,12]. A human homolog of BOR1
named NaBC1has been reported to be present in mammalian cell
lines and to enhance cell proliferation at low BA concentrations
[13], but this has yet to be confirmed by another laboratory. The
effect of BA on growth and cell proliferation in trout, zebrafish and
the mammalian HEK and HeLa cells follows an inverted U-shape
with higher concentrations causing cell growth inhibition [13–15].
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Concentrations of 60 to 100 mM BA inhibit cell proliferation in
prostate cancer cells whereas high concentrations of 500 to
1000 mM BA are required to inhibit the proliferation of non-tumor
prostate epithelial cells over the same time frame [16].
Human blood levels of BA reflect the local geology, water
quality, and plants in the diet with a world-wide range from 2 to
120 mM (21 to 1232 ng B/g wet blood) in free living healthy men
and women [17,18]. Several human studies have observed a
decrease in the risk of prostate and lung cancer, and abnormal
cervical cytopathology in proportion to the amount of B ingested
from food and water [19–22]. One study did not observe a
protective effect, but differed from other studies in using a different
B food database and estimated B content of some foods [23,24].
The biological plausibility for the chemopreventative effect of
BA is supported by several lines of investigation. In immunocom-
promised mice, BA supplementation reduced the growth of
transplanted human prostate tumors, decreased IGF-1 tissue
concentrations, and lowered serum prostate specific antigen levels
[25]. In cell culture, BA reduced the proliferation of human cancer
prostate cell lines in a dose dependent manner and inhibited cell
migration and invasion [16,26,27]. We discovered the relationship
between BA’s ability to inhibit prostate cancer cell proliferation
and calcium signaling after mass spectrometry studies showed the
affinity of BA for NAD+ was reduced by phosphorylation and
therefore potentially subject to biological regulation [28,29]. BA
was also shown to be a non-competitive inhibitor of ADP-ribosyl
cyclase [30]. This led us to study its impact on the NAD+/cADPR
Ca2+ release pathway. We showed that pharmacological levels of
BA (250 and 1000 mM), but not methylboronic acid, decreased
NAD+ stimulated release of Ca2+ without affecting calcium release
when applied on its own [27]. It was not clear from these studies if
BA was inhibiting Ca2+ release by interfering with NAD+
conversion to cADPR, blocking release of Ca2+ stores, or
interfering with CCE. It also raised the possibility that BA
concentrations in the normal blood range might be able to inhibit
Ca2+ release from ryanodine receptor (RyR) sensitive stores. Here
we demonstrate that physiological levels of BA inhibit Ca2+ release
from RyR responsive stores in human prostate epithelial cells and
lower luminal Ca2+ levels.
Methods
Cell Cultures
Experiments used prostate cancer cell lines DU-145 and
LNCaP and the non-tumor cell line PWR1E. Cells were grown
and maintained in cell culture plates at 37uC in 95% air and 5%
CO2 humidified incubator. For confocal experiments, cells were
cultured on glass cover slips for 24 hours prior to performing
assays and studied at a confluency of less than 80%. DU-145 and
PWR1E cells were acquired from American Type Culture
Collection (ATCC, Manassas, VA) and LNCaP was a gift from
Dr Allen Pantuck of the Department of Urology, Geffen School of
Medicine at the University of California, Los Angeles. RPMI cell
culture media was supplemented with 10% fetal bovine serum
(FBS), penicillin (100 U/ml), streptomycin (100 mg/ml), and L-
glutamine (200 mM). PWR1E non-tumor cells were maintained in
Keratinocyte media containing streptomycin (100 mg/ml), L-
glutamine (200 mM), 2.5 mg human recombinant EGF, and
25 mg of bovine pituitary extract (Gibco, Carlsbad, CA). Boron
depleted media was prepared using the boron specific ionic
exchange resin, Amberlite IRE-743 (Sigma) as previously
described [16] and modified as follows. Nine grams of autoclaved
IRA-743 ion exchange resin were added to 500 ml media and
mixed on an Orbit rotator at 75 to 100 rpm for 15 to 20 hrs at
9uC.
Measurement of Ca2+ Transients
Storage Ca2+ changes were monitored using the calcium
sensitive dye Rhod-2, AM ester (Biotium, Hayward, CA) which
accumulates in organelles. Rhod-2, AM ester has a Kd of 1 mM
and has been shown to compartmentalize, particularly in the
mitochondria, but as we show, in other organelles as well (Fig. 1).
We also used ER Tracker green and Mito Tracker green
(Molecular Probes, Carlsbad, CA) in conjunction with Rhod-2,
Am ester. They are highly specific fluorescent labels for the
endoplasmic reticulum and mitochondria, respectively. We
analyzed Ca2+ changes in response to BA and various agonists
by selecting regions of interest in cells that overlapped the red
Figure 1. DU-145 cells demonstrating fluorescently labeled
stored calcium, ER and mitochondria. A. Two DU-145 cells labeled
with red fluorescent intracellular calcium fluorophore, Rhod-2, and
green fluorescent endoplasmic reticulum label, ER tracker. Yellow
indicates overlap of Ca2+ and ER and the circle is the region of interest
(ROI) analyzed in these experiments. Arrows indicate organelles: nucl
(nucleolus), nuc (nucleus), ER (endoplasmic reticulum) B. Two DU-145
cells labeled with red fluorescent intracellular Ca2+ fluorophore, Rhod-2,
and green fluorescent mitochondrial label, Mito tracker. Yellow
indicates overlap of calcium and mitochondria. Arrows indicate
organelles: nucl (nucleolus), nuc (nucleus), mt (mitochondria).
doi:10.1371/journal.pone.0006009.g001
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Rhod-2 Ca2+ label with the green ER tracker (Fig. 1A) [31–33].
Rhod-2, AM ester was prepared as a 1 mM stock solution in
DMSO and diluted in either complete RPMI media or complete
Keratinocyte media to 3 mM. Cells were incubated with Rhod-2
AM ester (5 mM) and ER or Mt Tracker (0.5 mM, 250 nM
respectively) in RPMI or Keratinocyte media for 30 minutes at
37uC. Ca2+ release was stimulated using agonists in combination
with different concentrations of BA in Ringers solution. Images
were collected with a Zeiss 510 LSM 5 Pascal mounted to an
upright microscope (Zeiss Axioplan 2) equipped with an Axoplan
X63 (NA 0.95) water immersion objective. A HeNe laser was used
to excite Rhod-2 at 543 nm. 488 nm from a laser diode was used
to excite ER or Mt Tracker. The emission was collected on a
photomultiplier tube through a 560 nm LP filter for Rhod-2 and a
505 LP filter for ER and Mito trackers. Additional magnification,
time series, and background subtraction were controlled using
Zeiss LSM acquisition software. All images were acquired as 12
bit.
Analysis of Ca2+ release using confocal microscopy
BA treatments were applied in Ca2+ free Ringer’s solution
prepared using ultrapure water to remove B [16,34]. Ca2+ release
from the RyR was activated by the addition of either 25 mM
cADPR to 10 mM digitonin permeabilized cells, or 20 mM
caffeine or 100 mM 4-chloro-m-cresol (4cmc) in intact cells
[35,36]. Inhibition of Ca2+ release was achieved using 10 mM
dantrolene or varying concentrations of BA in the presence of an
agonist [37]. SERCA was inhibited using 10 mM cyclopiazonic
acid (CPA) [2]. All drug applications were for a 30 second
duration in calcium free Ringer’s solution (143 mM NaCl, 5 mM
KCl, 1 mM MgCl2, 10 mM glucose, 10 mM HEPES, 1 mM
EGTA-2H2O, 1 mM EGTA) in order to view Ca
2+ release from
the stores without input of external Ca2+. Drug application was
followed by a three minute wash in Ringer’s solution containing
calcium (140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mMMgCl2,
10 mM glucose, 10 mM HEPES). Solutions were delivered to the
perfusion chamber at a rate of 1 ml/min by using a single-pass,
gravity-feed perfusion system. Confocal images were taken every
second and began 2 minutes prior to the first treatment
application in order to establish a base line of fluorescence
intensity. The change in fluorescence intensity (f) caused by the
drug application was compared to an averaged baseline measure-
ment which consisted of three measurements prior to the
application of the drug (fo). All measurements were normalized
to the base line in this manner using the ratio f-fo/fo. Typically 6–
10 cells were analyzed in one field of view and all experiments
were performed on a minimum of three independent preparations.
The order of drug application was based on an initial experiment
involving consecutive agonist-only applications. If the 2nd
application of agonist caused a lower Ca2+ release than the 1st,
cells were treated with agonist plus BA first. This avoided the
possibility that measured inhibition of Ca2+ release due to BA was
in part due to refractory cells made so by prior treatment with
agonist.
Analysis of stored calcium levels
DU-145 prostate cancer cells were treated with BA for 1 to
72 hrs in media stripped of boron using Amberlite IRA-743 ion-
exchange resin (Sigma-Aldrich, St. Louis, MO) as previously
described. Just prior to analysis cells were removed from the plate
using 1% trypsin digestion, centrifuged, and labeled for 45 minutes
in standard media with 3 mM Rhod-2 AM ester for storage Ca2+
analysis. In order to monitor cytoplasmic Ca2+ levels, cells were
labeled with 5 mM Indo-1 AM (Invitrogen, Carlsbad, CA) for 45
minutes. Labeled cells were then washed and resuspended in 1 mL
of normal media. Fluorescence was analyzed using a Beckton
Dickinson BD-LSR I analytic flow cytometer. Rhod-2 excitation
was achieved with a 514 nm argon laser and analyzed in the
(581 nm) FL-2 channel. Indo-1 was excited with a UV laser
(351 nm) and analyzed on 400 nm (FL5) and 510 nm (FL4) band-
pass filters. Results for Indo-1 labeled cells are given as ratios of
fluorescence (FL5/FL4). Forward and side scatter were used to
gate out cellular fragments [38]. Raw flow cytometry data was
analyzed using FLOWJO software (Treestar Software, San Carlos,
CA, USA). Results are presented as% Ca2+ levels compared to
untreated cells. Storage Ca2+ levels were also analyzed in BA
treated and non-treated cells by comparing Ca2+ storage emptying
in response to 100 mM thapsigargin using confocal microscopy
[39].
Statistical analysis of the data
Data are presented as mean6SD and were analyzed using
Student’s paired or unpaired t-test or one-way ANOVA for
multiple comparisons with Dunnett’s multiple comparison post-
hoc test using Graphpad Prism 4.0. A p value,0.05 was
considered to be statistically significant. The equation for non-
linear one site binding (hyperbola) Y=Bmax*X/(Kd+X) was used
to calculate Kd and Bmax values using Graphpad software.
Chemicals and supplies
B was removed from water and media using methods previously
described [13]. Caffeine, 4-CmC, ATP, CPA, dantrolene,
thapsigargin, cADPR, digitonin and boric acid were obtained
from Sigma (St. Louis, MO) diluted in calcium free Ringer’s
Solution to ensure that if DMSO was present levels were no
greater than 0.1%. All solutions were prepared fresh prior to
perfusion. Superfusion with 0.1% DMSO in calcium free Ringer’s
solution did not affect ER Ca2+ levels or imaging responses.
Results
The objective of the study was to determine if physiological
concentrations of BA inhibit the release of Ca2+ from RyR
sensitive stores in human prostate cancer and non-tumor epithelial
cells. DU-145 cells were loaded with Rhod-2 and ER tracker or
Mito tracker to determine if Rhod-2 compartmentalized in one or
both compartments. It was not possible to delineate Ca2+ signaling
from the ER versus mitochondria in live cells using confocal
microscopy. Rhod-2 labeled Ca2+ in mitochondria, ER, nucleolus,
and other areas in the cell (Fig. 1A–B). In our experiments, a
combination of ER Tracker and Rhod-2 were used to define our
regions of interest on sites of stored Ca2+ (Fig. 1A). This area
included Ca2+ stores located in the ER and mitochondria (Fig. 1A–
B). Application of BA from 0.1–1000 mM alone did not
demonstrate an immediate measurable effect on storage Ca2+
using confocal microscopy (data not shown).
Boric acid inhibits Ca2+ release in response to ryanodine
receptor agonists
To determine if BA inhibited Ca2+ release from the RyR, we
treated DU145 cells with three different RyR agonists in
combination with BA. Competitive ligand binding analysis showed
BA was a single site reversible competitive inhibitor of cADPR, an
endogenous agonist of RyR (Fig. 2A–C). The equilibrium
dissociation constant, (KD) for cADPR was 15.10, but in the
presence of BA increased to 49.39. Inhibition by BA was reversed
by increasing the concentration of cADPR and the presence of BA
Boron Inhibits Ca2+ Release
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did not change the maximum number of binding sites (Bmax)
(Table 1).
We then analyzed the effect of BA on other RyR agonists in
intact cells. We first used caffeine [20 mM] an agonist that
potentiates RyR sensitivity to its native ligand, Ca2+. In response
to two consecutive applications of caffeine, the second release was
slightly greater than the first (Fig. 3A). This sequence was then
repeated with BA added in combination with caffeine in the
second application. The results of these experiments show that BA
reduced Ca2+ release in a dose dependent manner from 10 to
150 mM BA (Fig. 3B–F). We then examined the effect of BA on
4CmC, a direct agonist of the RyR. Consecutive applications of
50 mM 4CmC resulted in equivalent Ca2+ release (Fig. 4A). As
observed with caffeine, BA decreased 4CmC stimulated Ca2+
release in a dose dependent manner (Fig. 4B–E). However,
inhibition began at 1 mM BA and reached a maximum at 10 mM
BA.
Previous studies have shown that the inhibitory effect of BA on
cell proliferation at the IC50 for DU-145 cells was approximately
10% less effective on the less aggressive LNCaP prostate cancer
cell line. In addition, BA was not able to achieve a 50% reduction
in proliferation in non-tumor PWR1E prostate epithelial cells in
experiments using up to 4 times the IC50 for DU145 [16]. We
examined these cell lines to determine if BA was also less effective
in inhibiting caffeine sensitive Ca2+ release. Inhibition of Ca2+
release in response to caffeine in LNCaP prostate tumor cells
occurred over 20 mM-150 mM BA (Fig. 5A–D). Thus, LNCaP
cells were less sensitive to BA compared to DU-145. LNCaP cells
were not responsive to 4CmC treatment (not shown). The PWR1E
non-tumor, hyperplasic prostate cell line required 150 mM BA to
inhibit caffeine stimulated Ca2+ release (Fig. 6A–D). PWR1E cells
were non-responsive to 4CmC treatment (not shown).
Boric acid inhibits cyclopiazonic acid induced Ca2+
release from the ER
The release of ER Ca2+ stores in some non-excitable cells can be
stimulated using cyclopiazonic acid (CPA) which inhibits SERCA
in a manner similar to thapsigargin, but can be washed out [40].
BA (0.1–1000 mM) by itself did not alter storage calcium levels
during the time course of the experiment (not shown). Responses
to consecutive applications of CPA [10 mM] did not decay
(Fig. 7A). Simultaneous application of CPA and 1 mM BA caused
a significant decrease in release and 10 mM BA caused near
Table 1. Competitive Ligand Binding Study of cADPR and
Boric Acid on Ryanodine Receptor Ca2+ Release.
Best Fit Values
Parameter cADPR cADPR+BA
Bmax 116.463.5a 144.8611.9
Kd 15.161.6 49.469.1
95% Confidence
Bmax 109.3 to 123.4 120.8 to 168.8
Kd 11.9 to18.3 31.0 to 67.8
Goodness of Fit
Degrees of Freedom 41 40
R2 0.9155 0.8606
Absolute Sum of Squares 2522 6745
aStandard error of mean.
doi:10.1371/journal.pone.0006009.t001
Figure 2. Calcium release in permeabilized DU-145 cells in
response to cADPR with and without 50 mM BA present. A.
50 mM BA inhibited 25 mM cADPR induced Ca2+ release (n = 6;
***p,0.001). B. Competitive ligand binding study showed BA was a
surmountable competitive antagonist of cADPR in a single site model.
Concentrations of BA were held at 50 mM. At low cADPR concentrations
BA shifted the Ca2+ release response to the right, but this was reversed
at higher cADPR concentrations and the maximum response (Bmax)
was not changed. Each data point is the mean of n = 6. R2 is 0.9155 and
0.8606 for cADPR without and with BA, respectively.
doi:10.1371/journal.pone.0006009.g002
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complete inhibition (Fig. 7B–D). We then tested the effect of
dantrolene, a known inhibitor of the RyR on Ca2+ release by CPA.
We found that 10 mM dantrolene inhibited CPA stimulated Ca2+
release at a level equivalent to 10 mM BA (Fig. 8A–B).
Boric acid treatment lowers storage [Ca2+] with no effect
on cytoplasmic [Ca2+]
Our results showing BA inhibited Ca2+ release lead us to
analyze relative [Ca2+]st levels using Rhod-2 stained cells and
relative [Ca2+ ]cyt levels using Indo-1 stained cells and flow
cytometry. Exposure of DU-145 cells to BA [10–50 mM] for
24 hours did not affect [Ca2+ ]cyt (Fig. 9A). However, reductions
[Ca2+]st (22%) occurred with 10 mM BA resulted in a 32%
reduction in [Ca2+]st by 50 mM BA at 1 hour (Fig. 9B). Neither
higher BA concentrations nor treatment with 10 mM BA up to
72 hours resulted in further reduction in [Ca2+ ]st (Fig. 9BC). We
then conducted confocal measurements of thapsigargin stimulated
Ca2+ release after DU-145 cells were pretreated with BA (50 mM)
for 24 hrs and observed a 35% decrease in Ca2+ release (Fig. 9D).
Discussion
This study reports the unexpected finding that stored Ca2+
release and luminal levels can be modulated by physiologically
relevant levels of BA in DU-145 prostate cancer epithelial cells.
This is relevant to our understanding of cancer risk since blood
levels of BA are determined by the consumption of B in drinking
water and plant derived foods [17]. It is likely to be the first cellular
response to B exposure and thus a starting point for understanding
how the risk of prostate and lung cancer is reduced by B in a dose
dependent manner [16,21,22]. BA exhibited the attributes of a
classic antagonist in that it did not have an immediate effect on
Ca2+ release when applied by itself and its effects were agonist
dependent. BA dose dependently inhibited Ca2+ release in
response to cADPR, an endogenous agonist of the RyR, and
agonists caffeine and 4-CmC (Fig. 2–5). In our competitive ligand
binding analysis, BA displayed the characteristic of a single site
antagonist in that it was reversible at higher concentrations of
cADPR (fig. 2B). BA increased Kd, from 15.1 to 49.4, but did not
affect BMax (Table 1). BA has been shown to bind to cADPR at
high concentrations, however, BA’s ability to inhibit cADPR,
caffeine and 4CmC induced Ca2+ release indicates that at
physiological concentrations BA may bind to the cADPR binding
site on the RyR stabilizing the Ca2+ channel in its inactive state
[30].
Proliferation of LNCaP cells have been reported to be about
10% less sensitive and PWR1E non-tumor cells are more than 4
fold less sensitive to BA than DU-145 cells [16]. We also observed
this pattern of sensitivity in BA’s ability to inhibit caffeine
stimulated Ca2+ release. The lowest effective concentration for
DU-145 was 10 mM BA, LNCaP was 20 mM BA, and PWR1E
was 150 mM BA (Fig. 3F, 5D & 6D). In addition to the decreased
responsiveness to BA, both LNCaP and PWR1E were non-
Figure 3. Boric acid inhibits Ca2+ release in response to
ryanodine receptor agonist caffeine in DU-145 cells. A. Ca2+
release in DU-145 cells in response to consecutive applications of
20 mM caffeine (n = 6, *p = 0.0168). B. 10 mM BA significantly inhibited
Ca2+ release (n = 6, **p,0.01). C. 20 mM M BA significantly inhibited
Ca2+ release (n = 6, *p = 0.0163). D. 50 mM BA significantly inhibited Ca2+
release (n = 6, **p= 0.0042). E. 150 mM BA significantly inhibited Ca2+
release, n = 6, ***p = 0.0001. F. combined data analysis showing
inhibitory dose response effect of BA on caffeine stimulated Ca2+
release, (n = 6 per concentration, **p,0.01). Figures 2–9, each bar
represents the mean response of 6 experiments (n = 6) replicated 3
times. The line scans on the right of each bar graph are representative
responses from a single experiment.
doi:10.1371/journal.pone.0006009.g003
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Figure 4. Boric acid inhibits Ca2+ release in response to
ryanodine receptor agonist 4-CmC (50 mM) in DU-145 cells. A.
Consecutive applications of 4-CmC did not alter the calcium release
response (n = 6, NS). B. 0.1 mM BA did not inhibit Ca2+ release. C. 1.0 mM
BA inhibited Ca2+ release (n = 6, *p,0.05). D. 10 mM BA inhibited Ca2+
release (n = 6, ***p = 0.0005). E. Combined data analysis showing a dose
dependent Ca2+ release response (n = 6 per concentration (**p,0.01).
doi:10.1371/journal.pone.0006009.g004
Figure 5. Boric acid inhibition of caffeine (20 mM) stimulated
Ca2+ release in LNCaP cells. A. 20 mM BA inhibition of calcium
release (n = 6, *p = 0.0226). B. 50 mM BA inhibition of Ca2+ release (n = 6,
**p = 0.0019). C. 150 mM BA inhibition of caffeine induced Ca2+ release
(n = 6, ***p,0.0001). D. Combined data showing concentration
dependent inhibition of caffeine stimulated release (n = 6, **p,0.01).
doi:10.1371/journal.pone.0006009.g005
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responsive to 4CmC treatment. RyR isoforms 1 and 2, but not 3
are known to be activated by 4CmC in some cell lines [41]. It is
possible that cell line differences were due to differences in RyR
isoforms or their expression. LNCaP cell lines have been shown to
express RyR 1 and 2, but not 3 [42]. We were unable to locate
studies in the literature that identified RyR isoforms in DU-145 or
PWR1E cells in any prostate cell line.
Renal function tests have shown BA is reabsorbed by the kidney
in non-pregnant and pregnant women [43]. The discovery of an
electrogenic, voltage-regulated bicarbonate sodium-coupled bo-
rate co-transporter (NaBC1) in rat kidney tubules may explain this
observation, but it has not yet been confirmed by another
laboratory. NaBC1 expression induced proliferation in HEK and
Hela cells by activation of the MAPK pathway 16 hours post-
treatment [13]. It is unknown at this time whether NaBC1 is
expressed in prostate tumor and non-tumor cell lines, but
Figure 6. Boric acid inhibition of caffeine (20 mM) stimulated
Ca2+ release in PWR1E non-tumor cells. A. Consecutive caffeine
applications in PWR1E prostate cell. (n = 6, NS). B. 50 mM BA and caffeine
induced Ca2+ release shows no inhibition (n = 6, NS). C. 150 mM BA
inhibited caffeine induced Ca2+ release (n = 6, **p = 0.0029). D.
Combined data showing no dose response and inhibition only at
150 mM (n= 6, *p,0.05).
doi:10.1371/journal.pone.0006009.g006 Figure 7. Boric acid inhibits CPA (10 mM) induced Ca2+ release
from the ER in DU-145 cells. Cells were tested with CPA+BA
followed by CPA. A. Consecutive applications of CPA did not alter Ca2+
release (n = 6, NS). B. 0.1 mM M BA did not inhibit CPA stimulated Ca2+
release (n = 6, NS). C. 1.0 mM BA inhibited CPA stimulated Ca2+ release
(n = 6, **p= 0.0037). D. 10 mM BA inhibited CPA stimulated Ca2+ release
(n = 6, ***p,0.0001).
doi:10.1371/journal.pone.0006009.g007
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differences in its expression has been raised as a possible
explanation for the variation in cellular sensitivity to BA between
prostate tumor and non-tumor cells [10].
To further explore BA’s ability to inhibit stored Ca2+ release we
tested its effects in the presence of CPA (Fig. 7–8). CPA inhibits the
SERCA channel resulting in emptying of Ca2+ stores [44]. Our
study showed that BA dose dependently blocked CPA mediated
Ca2+ release in DU-145 cells. We also observed a reduction of
storage Ca2+ levels by 22% to 32% in 10 to 50 mM BA treated
DU-145 cells compared to untreated cells. STIM proteins are
involved in triggering Ca2+ influx into the ER [45–48]. If BA
reduces Ca2+ leakage through RyR channels the major loss by
leakage may occur through presenilins and other non-channel
proteins that do not stimulate STIM proteins. This would result in
decreased stored Ca2+ levels that are unable to signal refilling.
The importance of Ca2+ in cell cycle control and proliferation is
a well established area of cancer research, but it has not been
studied as a mode of action in cancer prevention [49–51]. BA’s
ability to modulate cell proliferation has been linked to changes in
the expression of cyclins and the MAPK pathway in DU-145,
HEK293 and HeLa cells [13,16,26]. However, it is possible these
effects occur in response to reductions in Ca2+ release or storage.
In the prostate cancer LNCaP cell line, Humez observed that IGF
(5 ng/ml), which increases cell growth, increased ER [Ca2+]ER,
whereas TNF alpha (1 ng/ml), which reduces cell proliferation,
reduced [Ca2+]ER [52].
In conclusion, BA has previously been reported to reduce the
risk of prostate cancer in humans and reduce tumor growth and
prostate cancer cell proliferation, migration, and invasion. Our
results demonstrate that physiological levels of BA inhibit agonist
Figure 8. Dantrolene inhibits CPA induced Ca2+ release in DU-
145 cells. A. Cells were tested with CPA (10 mM)+dantrolene (10 mM)
followed by CPA (n = 6, ***p,0.0001. B. BA inhibited CPA stimulated
Ca2+ release in a concentration dependent manner. The inhibitory effect
of dantroline and BA were equivalent at 10 mM, CPA (n = 6, ** p,0.01).
doi:10.1371/journal.pone.0006009.g008
Figure 9. Boric acid treatment lowers luminal storage [Ca2+]st,
but has no effect on cytoplasmic [Ca2+]cyt in DU-145 cells. A.
Relative [Ca2+]cyt following exposure to 0, 10 and 50 mM BA for 24 hrs
(n = 5, NS). B. [Ca2+]st as percent of 0 treatment in DU-145 cells treated
with 0–250 mM BA for 24 hrs. Boric acid [10–50 mM] reduced ER calcium
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stimulated release of stored Ca2+ in a dose dependent manner and
lower stored Ca2+ storage levels. This suggests that BA’s ability to
dampen Ca2+ signaling in cancer cells underlies its ability to
reduce clinical cancer risk.
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